Document is current
Any future updates will be listed below
-
Authors
Sharma, Piyush https://orcid.org/0000-0003-1185-9534
Guo, Ao
Poudel, Suresh
Boada-Romero, Emilio https://orcid.org/0000-0003-2482-076X
Verbist, Katherine C.
Palacios, Gustavo https://orcid.org/0009-0001-2483-3774
Immadisetty, Kalyan
Chen, Mark J. https://orcid.org/0000-0003-1169-563X
Haydar, Dalia
Mishra, Ashutosh
Peng, Junmin https://orcid.org/0000-0003-0472-7648
Babu, M. Madan https://orcid.org/0000-0003-0556-6196
Krenciute, Giedre https://orcid.org/0000-0003-4335-0644
Glazer, Evan S. https://orcid.org/0000-0002-5796-0542
Green, Douglas R. https://orcid.org/0000-0002-7332-1417
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI123322)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA231620, K99CA256262)
- License Information
-
More Information
Article History
Received: 25 November 2024
Accepted: 13 June 2025
First Online: 23 July 2025
Competing interests
: E.S.G. consults for Anviron and G.K. has patent applications in the fields of cell or gene therapy for cancer and has received honoraria from Cell Signaling and Kineticos within the last 2 years. During the course of this research, D.R.G. consulted for Sonata Therapeutics, Ventus Therapeutics, Mycos and ASHA Therapeutics, and received honoraria, travel and/or research support from Horizon/Amgen, Lilly and Boeringher-Ingleheim. The other authors declare no competing interests.
